
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - Bacitracin, the widely used topical antibiotic, has been named "Contact Allergen of 2003."






